Cancer Genetics, Inc. announced that it was selected by ReproCELL, Inc., to provide next-generation sequencing (NGS) based services and molecular information to enhance ReproCELL's translational medicine initiatives. Under the terms of the agreement, CGI will perform NGS using its recently launched Focus::Hotspot panel. This panel targets clinically actionable and validated mutations found in several of the most common solid tumors including breast, colorectal, and lung cancers.

CGI expects to process several thousand samples over the next two years at the Company's genomic lab in Hyderabad, India to aid ReproCELL in advancing its product development portfolio.